Biomarin Pharmaceutical Inc U.S. Food and Drug Administration Approves ROCTAVIAN Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the BioMarin Pharmaceutical, U.S. Food and Drug Administration approves BioMarin's Roctavian, the first and only gene therapy for adults with severe hemophilia A webcast. (Operator Instructions) And please be advised that this call is being recorded. (Operator Instructions).
And now at this time, I'll turn things over to Ms. Traci McCarty, Head of Investor Relations at BioMarin. Traci, please go ahead.
Thank you, Bill, and thank you all for joining us this afternoon. On the call from BioMarin today, we have JJ Bienaime, Chairman and CEO; Hank Fuchs, President, Worldwide Research and Development; Jeff Ajer, EVP, Chief Commercial Officer; Brian Mueller, EVP, Chief Financial Officer; and Greg Guyer, EVP, Chief Technical Officer, Manufacturing and Tech Operations.
To remind you, this nonconfidential presentation contains forward-looking statements about Roctavian and the business prospects of BioMarin Pharmaceutical Inc., including
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |